MARKET

ALDX

ALDX

Aldeyra Therapeutics Inc
NASDAQ
1.800
+0.020
+1.12%
After Hours: 1.780 -0.02 -1.11% 19:52 04/13 EDT
OPEN
1.720
PREV CLOSE
1.780
HIGH
1.835
LOW
1.700
VOLUME
1.49M
TURNOVER
--
52 WEEK HIGH
6.18
52 WEEK LOW
1.070
MARKET CAP
108.33M
P/E (TTM)
-3.1938
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ALDX last week (0406-0410)?
Weekly Report · 19h ago
ALDX SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds Aldeyra Therapeutics (ALDX) Investors of Securities Class Action Deadline on May 29, 2026
PR Newswire · 1d ago
ALDX Investors Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit Filed by The Rosen Law Firm
PR Newswire · 3d ago
AbbVie: Buy Or Sell Ahead Of Q1 Earnings? It's A Buy, But With Caveats (Upgrade)
Seeking Alpha · 4d ago
ALDX Investors Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit Filed by The Rosen Law Firm
Barchart · 6d ago
Shareholders who lost money in Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) Should Contact Wolf Haldenstein Immediately
PR Newswire · 6d ago
Weekly Report: what happened at ALDX last week (0330-0403)?
Weekly Report · 04/06 10:26
Aldeyra Therapeutics Sued Over Alleged Misrepresentations About Key Drug Trial Data
TipRanks · 04/03 15:34
More
About ALDX
Aldeyra Therapeutics, Inc. is a biotechnology company focused on discovering therapies designed to treat immune-mediated and metabolic diseases. The Company's approach is to develop pharmaceuticals that modulate protein systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Its product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX 248, ADX-743, ADX-631, ADX-246, and chemically related molecules for the potential treatment of systemic and retinal immune-mediated and metabolic diseases. Its late-stage product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the potential treatment of retinitis pigmentosa. ADX 629 is in Phase II clinical trials for moderate alcohol-associated hepatitis and Sjogren-Larsson Syndrome.

Webull offers Aldeyra Therapeutics Inc stock information, including NASDAQ: ALDX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALDX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ALDX stock methods without spending real money on the virtual paper trading platform.